Key Points:
• Follicular Lymphoma: The discussion includes the minimum workup required for treatment planning, frontline treatment options, nuances of PFS with different anti-CD20 agents, and considerations for relapse or refractory cases.
• Mantle Cell Lymphoma: The conversation delves into initial treatment paradigms, the role of BTK inhibitors, considerations for TP53 mutations, and options for relapsed or refractory cases, including the growing importance of CAR-T cell therapy.
In this episode of the Oncology Brothers podcast, Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center joins the hosts to discuss the current treatment landscape for low-grade lymphomas, specifically follicular and mantle cell lymphoma.
Dr. Torka emphasizes the importance of a thorough workup including history, physical, blood work, and imaging in determining the appropriate treatment plan for patients with follicular lymphoma. She highlights the different treatment options based on disease burden and patient symptoms, ranging from observation to chemoimmunotherapy.
For mantle cell lymphoma, Dr. Torka discusses the significance of Ki-67, TP53 mutation, and SOX11 in treatment decisions. She explains the evolving role of BTK inhibitors and the potential shift away from autotransplant in favor of incorporating BTK inhibitors upfront. The discussion also delves into the management of TP53 mutations and the promising results of combining BTK inhibitors with venetoclax.
In the relapse/refractory setting, Dr. Torka emphasizes the importance of considering CAR-T cell therapy as a preferred option for fit patients with mantle cell lymphoma. She also touches on the potential use of novel agents like pirtobrutinib and glofitamab in this space.
Overall, the episode provides a comprehensive overview of the current treatment options for low-grade lymphomas, highlighting the importance of personalized treatment approaches based on disease characteristics and patient factors. Dr. Torka's insights shed light on the evolving landscape of lymphoma treatment and the potential for improved outcomes with novel therapies.
